Advertisement
U.S. markets closed

Dynavax Technologies Corporation (DVAX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
11.70-0.35 (-2.90%)
At close: 04:00PM EDT
11.75 +0.05 (+0.43%)
After hours: 06:40PM EDT

Dynavax Technologies Corporation

2100 Powell Street
Suite 720
EmeryVille, CA 94608
United States
510 848 5100
https://www.dynavax.com

Sector(s)Healthcare
IndustryDrug Manufacturers - Specialty & Generic
Full Time Employees408

Key Executives

NameTitlePayExercisedYear Born
Mr. Ryan SpencerCEO & Director1.25MN/A1978
Mr. David F. NovackPresident & COO925.6kN/A1962
Ms. Kelly MacDonaldSenior VP & CFO674.27kN/A1984
Dr. Robert JanssenChief Medical Officer and Senior VP of Clinical Development, Medical & Regulatory Affairs789.76k35.66k1954
Mr. Justin BurgessPrincipal Accounting Officer & ControllerN/AN/AN/A
Mr. Jeff P. CoonCHRO and Senior VP of Human Resources & AdministrationN/AN/A1963
Mr. Paul CoxVP of Investor Relations & Corporate CommunicationsN/AN/AN/A
Mr. John SlebirSenior VP & General CounselN/AN/AN/A
Mr. Donn CasaleChief Commercial OfficerN/AN/AN/A
Dr. Dong YuSenior Vice President of Vaccine ResearchN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

Corporate Governance

Dynavax Technologies Corporation’s ISS Governance QualityScore as of March 1, 2024 is 5. The pillar scores are Audit: 4; Board: 5; Shareholder Rights: 7; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.